4.6 Article

LGR5 is expressed by Ewing sarcoma and potentiates Wnt/beta-catenin signaling

期刊

FRONTIERS IN ONCOLOGY
卷 3, 期 -, 页码 -

出版社

FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2013.00081

关键词

LGR5; Ewing sarcoma; stem cell; R-spondin; Wnt; beta-catenin

类别

资金

  1. Nancy Newton Loeb Pediatric Cancer Research Award
  2. [1R01-CA134604]
  3. [1U01 CA114757]
  4. [SU2C-AACR-IRG1309]
  5. [1R01CA138212-01]
  6. NATIONAL CANCER INSTITUTE [U54CA168512, T32CA009676, R01CA134604, R01CA138212, U01CA114757] Funding Source: NIH RePORTER

向作者/读者索取更多资源

Ewing sarcoma (ES) is an aggressive bone and soft tissue tumor of putative stem cell origin that predominantly occurs in children and young adults. Although most patients with localized ES can be cured with intensive therapy, the clinical course is variable and up to one third of patients relapse following initial remission. Unfortunately, little is yet known about the biologic features that distinguish low-risk from high-risk disease or the mechanisms of ES disease progression. Recent reports have suggested that putative cancer stem cells exist in ES and may contribute to an aggressive phenotype. The cell surface receptor leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5) is a somatic stem cell marker that functions as an oncogene in several human cancers, most notably colorectal carcinoma. LGR5 is a receptor for the R-spondin (RSPO) family of ligands and RSPO-mediated activation of LGR5 potentiates Wnt/beta-catenin signaling, contributing to stem cell proliferation and self-renewal. Given its presumed stem cell origin, we investigated whether LGR5 contributes to ES pathogenesis. We found that LGR5 is expressed by ES and that its expression is relatively increased in cells and tumors that display a more aggressive phenotype. In particular, LGR5 expression was increased in putative cancer stem cells. We also found that neural crest-derived stem cells express LGR5, raising the possibility that expression of LGR5 may be a feature of ES cells of origin. LGR5-high ES cells showed nuclear localization of beta-catenin and robust activation of TCF reporter activity when exposed to Wnt ligand and this was potentiated by RSPO. However, modulation of LGR5 or exposure to RSPO had no impact on proliferation confirming that Wnt/beta-catenin signaling in ES cells does not recapitulate signaling in epithelial cells. Together these studies show that the RSPO-LGR5-Wnt-beta-catenin axis is present and active in ES and may contribute to tumor pathogenesis.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Biochemistry & Molecular Biology

RNA helicase DDX3: a novel therapeutic target in Ewing sarcoma

B. A. Wilky, C. Kim, G. McCarty, E. A. Montgomery, K. Kammers, L. R. DeVine, R. N. Cole, V. Raman, D. M. Loeb

ONCOGENE (2016)

Article Oncology

Growing Pains: a Simulation-Based Curriculum for Improving the Transition to Hematology/Oncology Fellowship

Kim A. Reiss, Deepa Rangachari, David Cosgrove, Breelyn Wilky, Ross Donehower

JOURNAL OF CANCER EDUCATION (2017)

Review Oncology

Latest advances in adult gastrointestinal stromal tumors

Vaia Florou, Breelyn A. Wilky, Jonathan C. Trent

FUTURE ONCOLOGY (2017)

Review Oncology

Current and Future Directions for Angiosarcoma Therapy

Vaia Florou, Breelyn A. Wilky

CURRENT TREATMENT OPTIONS IN ONCOLOGY (2018)

Review Oncology

The current landscape of early drug development for patients with sarcoma in the immunotherapy era

Ana Sebio, Breelyn A. Wilky, Vicki L. Keedy, Robin L. Jones

FUTURE ONCOLOGY (2018)

Article Oncology

Malignant progression of a peripheral nerve sheath tumor in the setting of rhabdoid tumor predisposition syndrome

Santhosh A. Upadhyaya, Rose B. McGee, Breelyn A. Wilky, Alberto Broniscer

PEDIATRIC BLOOD & CANCER (2018)

Review Orthopedics

Local recurrence of soft-tissue sarcoma: issues in imaging surveillance strategy

Nisreen S. Ezuddin, Juan Pretell-Mazzini, Raphael L. Yechieli, Darcy A. Kerr, Breelyn A. Wilky, Ty K. Subhawong

SKELETAL RADIOLOGY (2018)

Article Oncology

Limb-sparing surgery plus radiotherapy results in superior survival: an analysis of patients with high-grade, extremity soft-tissue sarcoma from the NCDB and SEER

Stephen J. Ramey, Raphael Yechieli, Wei Zhao, Joyson Kodiyan, David Asher, Felix M. Chinea, Vivek Patel, Isildinha M. Reis, Lily Wang, Breelyn A. Wilky, Ty Subhawong, Jonathan C. Trent

CANCER MEDICINE (2018)

Article Oncology

Future directions in soft tissue sarcoma treatment

Francis Hall, Victor Villalobos, Breelyn Wilky

CURRENT PROBLEMS IN CANCER (2019)

Review Immunology

Immune checkpoint inhibitors: The linchpins of modern immunotherapy

Breelyn A. Wilky

IMMUNOLOGICAL REVIEWS (2019)

Article Oncology

Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial

Breelyn A. Wilky, Matte M. Trucco, Ty K. Subhawong, Vaia Florou, Wungki Park, Deukwoo Kwon, Eric D. Wieder, Despina Kolonias, Andrew E. Rosenberg, Darcy A. Kerr, E. Rosyni Sfakianaki, Mark Foley, Jaime R. Merchan, Krishna Komanduri, Jonathan C. Trent

LANCET ONCOLOGY (2019)

Review Surgery

Myoepithelial carcinoma or epithelioid sarcoma - A rare diagnosis with poor prognosis. A case report and review of literature

Kristina Khazeni, Hannah LaBove, Breelyn Wilky, Andrew E. Rosenberg, Elizabeth Paulus, Harvey Chim, Joseph M. Pearson, Danny Yakoub

INTERNATIONAL JOURNAL OF SURGERY CASE REPORTS (2018)

Article Oncology

A nonrandom association of sarcoidosis in patients with gastrointestinal stromal tumor and other sarcomas

Andrea P. Espejo, Jeremy L. Ramdial, Breelyn A. Wilky, Darcy A. Kerr, Jonathan C. Trent

RARE TUMORS (2018)

Article Medicine, Research & Experimental

From Vision to Reality: Deploying the Immune System for Treatment of Sarcoma

Breelyn A. Wilky, John M. Goldberg

DISCOVERY MEDICINE (2017)

Review Biotechnology & Applied Microbiology

Current status of immunotherapy for gastrointestinal stromal tumor

Y. Tan, J. C. Trent, B. A. Wilky, D. A. Kerr, A. E. Rosenberg

CANCER GENE THERAPY (2017)

暂无数据